Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections
Nader S. Abutaleb, Mohamed N. Seleem
Abstract
Clostridioides difficile , the leading cause of nosocomial infections, is an urgent health threat worldwide. The increased incidence and severity of disease, the high recurrence rates, and the dearth of effective anticlostridial drugs have created an urgent need for new therapeutic agents. In an effort to discover new drugs for the treatment of Clostridioides difficile infections (CDIs), we investigated a panel of FDA-approved antiparasitic drugs against C. difficile and identified diiodohydroxyquinoline (DIHQ), an FDA-approved oral antiamoebic drug.
Topics & Concepts
ClostridioidesDrug repositioningRepurposingDrugMedicineMicrobiologyIntensive care medicinePharmacologyBiologyInternal medicineEcologyClostridium difficile and Clostridium perfringens researchNosocomial Infections in ICUMicroscopic Colitis